Victoria, British Columbia Thursday, November 14, 2024, 18:00 Hrs [IST] ...
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...
23,24 In October 2021, tezepelumab was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA ...
7d
Net revenues of $16.4 million reported for the third quarter 2024 compared to $7.3 million in the second quarter 2024, over 120% sequential ...
Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...
EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...
The European Medicines Agency has approved Dupixent as the first treatment for eosinophilic esophagitis (EoE) in young children aged one to 11, m ...
The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age. Specifically, the approval covers children aged one to ...
Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...
Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one ...
Allergic reactions come in all varieties. One can even trigger a digestive disease called Eosinophilic Esophagitis, which ...
AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback